4/29/2013

The FDA granted fast-track status to Sanofi Pasteur and KaloBios Pharmaceuticals' KB001A, an experimental treatment for Pseudomonas aeruginosa-related pneumonia among people being treated with mechanical ventilation. The drug, a monoclonal antibody, is undergoing an early-stage study in the U.S.

Related Summaries